Plecanatide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Plecanatide
- Plecanatide: Original Indication Not Documented → Predicted Link to Hypertrichosis (Low-Confidence)
Plecanatide: Original Indication Not Documented → Predicted Link to Hypertrichosis (Low-Confidence)
One-Sentence Summary
Plecanatide (DrugBank DB13170) is described in the evidence pack as a locally-acting intestinal guanylate cyclase-C (GC-C) agonist with negligible systemic absorption, though its original approved indication is not documented in this evidence pack. The TxGNN model’s top prediction links plecanatide to hypertrichosis (excessive hair growth), with a prediction score of 99.998%, but zero clinical trials and zero literature records support this specific pairing — the model’s own accompanying rationale flags the result as likely noise rather than a genuine mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (no approved indication text available) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for plecanatide is not available in the structured drug.original_moa field. However, the mechanistic-link notes attached to every predicted indication in this pack consistently describe plecanatide as a guanylate cyclase-C (GC-C) agonist acting locally on the intestinal epithelium, with minimal systemic absorption — this is consistent with its known pharmacological class of GI-restricted secretagogues.
For the top-ranked prediction, hypertrichosis, the evidence pack’s own rationale states there is no known physiological pathway connecting intestinal GC-C/cGMP signaling to hair follicle growth regulation, and explicitly characterizes the high TxGNN score as likely model noise rather than a biologically grounded signal. This pattern repeats across all ten top-ranked predictions in this pack (hypertrichosis subtypes, congenital malformation syndromes, hair shaft disorders, Dandy-Walker malformation, coronary artery dissection, vascular disease, thoracic outlet syndrome, pheochromocytoma) — none have a plausible mechanistic link to a drug whose action is confined to the gut lumen, and none are supported by clinical trials.
The one prediction with attached literature (rank 3, “malformation syndrome with odontal/periodontal component”) returned 20 general periodontology papers that never mention plecanatide or GC-C signaling — a case of keyword co-occurrence rather than genuine drug-disease evidence. Overall, this evidence pack does not support a credible repurposing rationale for any of the top-10 candidates.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No NDA or marketing authorization records were found for plecanatide in this evidence pack (total_licenses: 0, market_status: 未上市/Not Marketed). The drug does not currently appear to hold an active license in this jurisdiction.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA/FDA-equivalent warning and contraindication data for plecanatide is flagged as a Blocking data gap (DG001) in this pack, meaning a formal safety assessment (S1 stage) cannot currently proceed without sourcing the official prescribing information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (hypertrichosis) has no clinical trial or literature support, and its own mechanistic rationale identifies it as probable model noise given plecanatide’s GI-restricted mode of action. This pattern holds across all ten top-ranked predictions in the pack — none reach beyond L5 (model-only) evidence, and the drug has no market presence or NDA in this jurisdiction to build on.
To proceed, the following is needed:
- Source TFDA/FDA prescribing information (warnings, contraindications) — currently a Blocking gap preventing any safety evaluation
- Obtain formal mechanism-of-action documentation (e.g., via DrugBank API) to replace the current data gap
- Independently verify whether any biologically plausible indication exists among lower-ranked TxGNN candidates, since the current top-10 all lack mechanistic or evidentiary support
- Re-run evidence collection (clinical trials, PubMed) once a more mechanistically plausible candidate indication is identified
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.